Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenalidomide (Revlimid) in Patients With Previously Treated Chronic Lymphocytic Leukemia.

Trial Profile

Lenalidomide (Revlimid) in Patients With Previously Treated Chronic Lymphocytic Leukemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jan 2018 Results (n=288) assessing clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia by taking data of this and other four studies, published in the Blood.
    • 15 Sep 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
    • 15 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top